Your browser doesn't support javascript.
loading
Atypical B cells are part of an alternative lineage of B cells that participates in responses to vaccination and infection in humans.
Sutton, Henry J; Aye, Racheal; Idris, Azza H; Vistein, Rachel; Nduati, Eunice; Kai, Oscar; Mwacharo, Jedida; Li, Xi; Gao, Xin; Andrews, T Daniel; Koutsakos, Marios; Nguyen, Thi H O; Nekrasov, Maxim; Milburn, Peter; Eltahla, Auda; Berry, Andrea A; Kc, Natasha; Chakravarty, Sumana; Sim, B Kim Lee; Wheatley, Adam K; Kent, Stephen J; Hoffman, Stephen L; Lyke, Kirsten E; Bejon, Philip; Luciani, Fabio; Kedzierska, Katherine; Seder, Robert A; Ndungu, Francis M; Cockburn, Ian A.
Afiliação
  • Sutton HJ; Department of Immunology and Infectious Disease, John Curtin School of Medical Research, The Australian National University, Canberra, ACT 2601, Australia.
  • Aye R; Department of Immunology and Infectious Disease, John Curtin School of Medical Research, The Australian National University, Canberra, ACT 2601, Australia; KEMRI - Wellcome Research Programme/Centre for Geographical Medicine Research (Coast), Kilifi, Kenya.
  • Idris AH; Vaccine Research Center, National Institutes of Allergy and Infectious Disease, National Institutes of Health, Bethesda, MD 20892, USA.
  • Vistein R; Vaccine Research Center, National Institutes of Allergy and Infectious Disease, National Institutes of Health, Bethesda, MD 20892, USA.
  • Nduati E; KEMRI - Wellcome Research Programme/Centre for Geographical Medicine Research (Coast), Kilifi, Kenya; Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine, University of Oxford, Oxford OX3 7FZ, UK.
  • Kai O; KEMRI - Wellcome Research Programme/Centre for Geographical Medicine Research (Coast), Kilifi, Kenya.
  • Mwacharo J; KEMRI - Wellcome Research Programme/Centre for Geographical Medicine Research (Coast), Kilifi, Kenya.
  • Li X; Department of Immunology and Infectious Disease, John Curtin School of Medical Research, The Australian National University, Canberra, ACT 2601, Australia.
  • Gao X; Department of Immunology and Infectious Disease, John Curtin School of Medical Research, The Australian National University, Canberra, ACT 2601, Australia.
  • Andrews TD; Department of Immunology and Infectious Disease, John Curtin School of Medical Research, The Australian National University, Canberra, ACT 2601, Australia.
  • Koutsakos M; Department of Microbiology and Immunology, Peter Doherty Institute, University of Melbourne, Melbourne, VIC 3000, Australia.
  • Nguyen THO; Department of Microbiology and Immunology, Peter Doherty Institute, University of Melbourne, Melbourne, VIC 3000, Australia.
  • Nekrasov M; Australian Cancer Research Foundation Biomolecular Resource Facility, John Curtin School of Medical Research, The Australian National University, Canberra, ACT 2601, Australia.
  • Milburn P; Australian Cancer Research Foundation Biomolecular Resource Facility, John Curtin School of Medical Research, The Australian National University, Canberra, ACT 2601, Australia.
  • Eltahla A; School of Medical Science, Kirby Institute, University of New South Wales, Sydney, NSW 2052, Australia.
  • Berry AA; Center for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, MD 21201, USA.
  • Kc N; Sanaria Inc., Rockville, MD 20850, USA.
  • Chakravarty S; Sanaria Inc., Rockville, MD 20850, USA.
  • Sim BKL; Sanaria Inc., Rockville, MD 20850, USA.
  • Wheatley AK; Department of Microbiology and Immunology, Peter Doherty Institute, University of Melbourne, Melbourne, VIC 3000, Australia; ARC Centre of Excellence in Convergent Bio-Nano Science and Technology, The University of Melbourne, Melbourne, VIC, Australia.
  • Kent SJ; Department of Microbiology and Immunology, Peter Doherty Institute, University of Melbourne, Melbourne, VIC 3000, Australia; ARC Centre of Excellence in Convergent Bio-Nano Science and Technology, The University of Melbourne, Melbourne, VIC, Australia.
  • Hoffman SL; Sanaria Inc., Rockville, MD 20850, USA.
  • Lyke KE; Center for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, MD 21201, USA.
  • Bejon P; KEMRI - Wellcome Research Programme/Centre for Geographical Medicine Research (Coast), Kilifi, Kenya; Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine, University of Oxford, Oxford OX3 7FZ, UK.
  • Luciani F; School of Medical Science, Kirby Institute, University of New South Wales, Sydney, NSW 2052, Australia.
  • Kedzierska K; Department of Microbiology and Immunology, Peter Doherty Institute, University of Melbourne, Melbourne, VIC 3000, Australia.
  • Seder RA; Vaccine Research Center, National Institutes of Allergy and Infectious Disease, National Institutes of Health, Bethesda, MD 20892, USA.
  • Ndungu FM; KEMRI - Wellcome Research Programme/Centre for Geographical Medicine Research (Coast), Kilifi, Kenya; Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine, University of Oxford, Oxford OX3 7FZ, UK.
  • Cockburn IA; Department of Immunology and Infectious Disease, John Curtin School of Medical Research, The Australian National University, Canberra, ACT 2601, Australia. Electronic address: ian.cockburn@anu.edu.au.
Cell Rep ; 34(6): 108684, 2021 02 09.
Article em En | MEDLINE | ID: mdl-33567273
ABSTRACT
The diversity of circulating human B cells is unknown. We use single-cell RNA sequencing (RNA-seq) to examine the diversity of both antigen-specific and total B cells in healthy subjects and malaria-exposed individuals. This reveals two B cell lineages a classical lineage of activated and resting memory B cells and an alternative lineage, which includes previously described atypical B cells. Although atypical B cells have previously been associated with disease states, the alternative lineage is common in healthy controls, as well as malaria-exposed individuals. We further track Plasmodium-specific B cells after malaria vaccination in naive volunteers. We find that alternative lineage cells are primed after the initial immunization and respond to booster doses. However, alternative lineage cells develop an atypical phenotype with repeated boosts. The data highlight that atypical cells are part of a wider alternative lineage of B cells that are a normal component of healthy immune responses.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Plasmodium / Anticorpos Antiprotozoários / Linfócitos B / Vacinação / Vacinas Antimaláricas / Malária Tipo de estudo: Clinical_trials Limite: Adult / Child / Child, preschool / Female / Humans / Male Idioma: En Ano de publicação: 2021 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Plasmodium / Anticorpos Antiprotozoários / Linfócitos B / Vacinação / Vacinas Antimaláricas / Malária Tipo de estudo: Clinical_trials Limite: Adult / Child / Child, preschool / Female / Humans / Male Idioma: En Ano de publicação: 2021 Tipo de documento: Article